Pharmaceutical Industry

FILE - In this Tuesday, Dec. 21, 2004, file photo, several Aleve tablets appear in front of bottles of the pain reliever, in Boston. Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other everyday aches and pains. (AP Photo/Steven Senne, File)

Business

FDA reconsiders heart safety of common pain pills

February 10, 2014 9:36 pm

Business

GlaxoSmithKline profits nearly triple in Q4

Washington Examiner -

February 5, 2014 5:14 pm

Business

Merck Q4 net drops 14 pct. on generic competition

Linda Johnson -

February 5, 2014 4:25 pm

Business

FDA clears first drug for blindness sleep disorder

Washington Examiner -

January 31, 2014 9:51 pm

Business

Lilly 4Q profit falls 12 pct, hurt by patent loss

Washington Examiner -

January 30, 2014 12:45 pm

Business

Stocks rise on Wall Street after 3 days of losses

Steve Rothwell -

January 28, 2014 10:31 pm

Recently, the FDA fast-tracked approval of a vaccine for the influenza strain H5N1, even though there had not yet been reported cases of H5N1, and the vaccine had been subjected to significantly less clinical research than the meningitis B vaccine. (Thinkstock)

Healthcare

FDA bureaucracy stifles access to life-saving drugs

Erik Telford -

January 23, 2014 5:00 am

Healthcare

FDA panel again rejects wider use of J&J’s Xarelto

Washington Examiner -

January 16, 2014 9:38 pm

Studies show not taking medications as prescribed leads to poorer health, more frequent hospitalization, a higher risk of death and as much as $290 billion annually in increased medical costs.ÃÂ But as any health care provider will tell you, the fact that actually taking a medication as prescribed is in a patientÃ¢â¬â¢s best interest does not lead to a patient doing what is in his best interest. (Photo: Thinkstock)

Op-Eds

Grandstanding AGs sue to stop drugmaker’s work to insure patients take medicine properly

Peter Pitts -

January 14, 2014 5:00 am

When it comes to biosimilars, we need to be extremely thoughtful about how we set policy relating to these promising medicines and strike a balance that promotes health and safety, rather than forcing a binary response that is driven by profits rather than patients. (Photo: Thinkstock)

Op-Eds

FDA must decide if a biosimilar rose by any other name is still a rose

Peter Pitts -

December 9, 2013 5:00 am

1...153154155 156 Page 154 of 156

Tag: Pharmaceutical Industry

FDA reconsiders heart safety of common pain pills

GlaxoSmithKline profits nearly triple in Q4

Merck Q4 net drops 14 pct. on generic competition

FDA clears first drug for blindness sleep disorder

Lilly 4Q profit falls 12 pct, hurt by patent loss

Stocks rise on Wall Street after 3 days of losses

FDA bureaucracy stifles access to life-saving drugs

FDA panel again rejects wider use of J&J’s Xarelto

Grandstanding AGs sue to stop drugmaker’s work to insure patients take medicine properly

FDA must decide if a biosimilar rose by any other name is still a rose

NEWS

POLICY

COMMENTARY

RESTORING AMERICA